机译:Pembrolizumab单疗法在老年PD-L1阳性晚期非小细胞肺癌中的安全性和有效性:来自Keynote-010,Keynote-024和Keynote-042研究的汇总分析
Natl Hosp Org Kyushu Canc Ctr Minami Ku Fukuoka Fukuoka 8111395 Japan;
Natl Hosp Org Nagoya Med Ctr Naka Ku 4-1-1 Sannomaru Nagoya Aichi 4600001 Japan;
Komagome Hosp Tokyo Metropolitan Canc &
Infect Dis Ctr Bunkyo Ku 3-18-22 Honkomagome Tokyo;
Netherlands Canc Inst Postbus 90203 NL-1006 BE Amsterdam Netherlands;
Inst Canc Estado Sao Paulo Av Dr Arnaldo 251 BR-01246000 Sao Paulo SP Brazil;
ARCN Lung Clin Grosshansdorf Wohrendamm 80 D-22927 Grosshansdorf Germany;
Guangdong Prov Peoples Hosp Guangdong Lung Canc Inst 106 Zhongshan 2nd Rd Guangzhou Shi 510080;
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins 1650 Orleans St Baltimore MD 21287 USA;
Vall dHebron Univ Hosp P Vall dHebron 119-129 Barcelona 08035 Spain;
MSD KK Chiyoda Ku Kitanomaru Sq 1-13-12 Tokyo 1028667 Japan;
MSD KK Chiyoda Ku Kitanomaru Sq 1-13-12 Tokyo 1028667 Japan;
MSD KK Chiyoda Ku Kitanomaru Sq 1-13-12 Tokyo 1028667 Japan;
Merck &
Co Inc 2000 Galloping Hill Rd Kenilworth NJ 07033 USA;
Merck &
Co Inc 2000 Galloping Hill Rd Kenilworth NJ 07033 USA;
Univ Miami Sylvester Comprehens Canc Ctr 1475 NW 12th Ave Miami FL 33136 USA;
Elderly; Pembrolizumab; Non small-cell lung cancer; Chemotherapy; Pooled analysis; Phase 3;
机译:Pembrolizumab单疗法在老年PD-L1阳性晚期非小细胞肺癌中的安全性和有效性:来自Keynote-010,Keynote-024和Keynote-042研究的汇总分析
机译:keynote-024的更新分析:Pembrozumab与铂族化疗,用于高级非小细胞肺癌,PD-L1肿瘤比例分数为50%或更高
机译:一线Pembrolizumab单药治疗老年患者(年龄> = 75岁)的疗效和安全性与非小细胞肺癌
机译:晚期卵巢癌患者的疗效和安全性分析
机译:Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
机译:派姆单抗单药治疗是否是PD-L1阳性晚期非小细胞肺癌老年患者的最佳治疗方法?
机译:PEMBROLIZUAB(PEMBRO)单药治疗(PEMBRO)单药(PEMBRO)对老年患者(PTS)的安全性和有效性,PD-L1阳性高级NSCLC:KEYNOTE-010,-024和-042的汇总分析